發(fā)布時間：2018-04-21 04:49

  本文選題：CYPC基因型 + 奧美拉唑　； 參考：《山東醫(yī)藥》2015年19期

【摘要】：目的觀察奧美拉唑在不同CYP2C19基因型幽門螺旋桿菌感染胃潰瘍患者體內(nèi)的藥代動力學及藥效學。方法幽門螺旋桿菌感染的胃潰瘍患者100例,根據(jù)CYP2C19主要基因型將其分為CYP2C19*1型組和CYP2C19*2型組各50例。兩組患者均接受奧美拉唑治療,比較兩組奧美拉唑藥時曲線下面積(AUC)、藥物半衰期(T1/2)、藥—時曲線的最高點稱峰濃度(Cmax)和血漿藥物達峰時間(Tmax)、抑酸起效時間(達到p H≥4所需時間)、抑酸持續(xù)時間(p H≥4持續(xù)時間)、幽門螺旋桿菌根治率。結(jié)果 CYP2C19*1型組、CYP2C19*2型組AUC分別為(1 059.8±159.9)、(1 251.1±235.9)ng/(m L·h),Cmax分別為(300.5±25.9)、(263.7±33.5)ng/m L,Tmax分別為(2.7±0.60)、(2.3±0.3)h,T1/2分別為(1.7±0.4)、(2.4±0.7)h,抑酸起效時間分別為(126.4±64.4)、(98.5±59.9)min,抑酸持續(xù)時間分別為(258.8±88.9)、(315.3±75.8)min,幽門螺旋桿菌根除率分別為70.0%、94.0%,兩組比較,P均0.05。結(jié)論較CYP2C19*1基因型,奧美拉唑在CYP2C19*2基因型幽門螺旋桿菌感染胃潰瘍患者體內(nèi)代謝快,有效時間長,幽門螺旋桿菌根除率高。
[Abstract]:Objective to observe the pharmacokinetics and pharmacodynamics of omeprazole in patients with gastric ulcer infected by Helicobacter pylori with different CYP2C19 genotypes. Methods 100 patients with gastric ulcer infected by Helicobacter pylori were divided into CYP2C19*1 type group and CYP2C19*2 type group according to their main genotypes of CYP2C19. Both groups were treated with omeprazole. The area under the time curve of omeprazole was compared between the two groups, the half life of the drug was T1 / 2, and the peak concentration of Cmaxwas at the highest point of the drug-hour curve, and the peak time of plasma drug reaching the peak was Tmax1, and the time of anti-acid effect (the time needed to reach pH 鈮，

本文編號：1780996